EU reveals proposals on pharma in TTIP talks
This article was originally published in Scrip
The European Commission has released a number of texts laying out the EU's proposals on specific issues, including pharmaceutical and medical device regulation, that are under discussion with the US government as part of the negotiations on the Transatlantic Trade and Investment Partnership (TTIP). The commission says this is the first time it has made such proposals public during bilateral trade talks, and that this "reflects its commitment to greater transparency in the negotiations".
You may also be interested in...
The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.
Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.
Medical device and pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from EU’s single market and customs union at the beginning of 2021.